Abstract 75P
Background
The sodium-dependent phosphate transporter NaPi2b is a promising target for the treatment of malignant tumors due to its increased expression in several oncological diseases. NaPi2b is a target for therapeutic monoclonal antibodies directed against the MX35 epitope within the large extracellular domain (ECD) of the NaPi2b. We assume that this epitope has tumor-specific conformation that is formed due to the creation of disulfide bonds between four cysteine residues at positions 303, 322, 328 and 350. The proline residue at position 325 lies between cysteines 322 and 328 in the region of the MX35 epitope of NaPi2b. We assume that proline at this position due to its formation of a bend in the structure of the peptide participates in the formation of a disulfide bond between cysteines at positions 322 and 328 that is critical in the recognition of the MX35 epitope by antibodies. To verify this, the mutant form with the proline replacement should be evaluated using antibodies against the MX35 epitope in Western blot and microscopy analysis. The aim of this work was to create a genetic construct encoding the mutant form of the NaPi2b transporter with the replacement of proline with alanine at position 325.
Methods
To carry out site-directed mutagenesis, we selected primers with the replacement of triplets encoding proline at position 325 with a triplet encoding alanine in the SLC34A2 (encoding transporter NaPi2b) gene. The resulting PCR product was transformed into E.coli cells of the XL1-Blue strain and plasmid DNA was isolated. To confirm the mutation, samples were sequenced using the Sanger method.
Results
As a result of our work, we created a genetic construct with the replacement of proline with alanine at position 325 of the NaPi2b transporter, which will be further test in Western blot and microscopy analysis by monoclonal antibodies.
Conclusions
The obtained results supported by the Kazan Federal University Strategic Academic Leadership Program (PRIORITY-2030) are important for further study of the mechanism of recognition of the MX35 NaPi2b epitope by monoclonal antibodies.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
Research Laboratory \"Biomarker\", Institute of Fundamental Medicine and Biology, Kazan Federal University.
Funding
This work has been supported by the Kazan Federal University Strategic Academic Leadership Program (PRIORITY-2030).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
20P - Effects of <italic>Apis dorsata</italic> honey on the expression of selected CYP450, pro-apoptotic, and anti-apoptotic genes during induced cytotoxicity in cyclophosphamide-treated human lung carcinoma (A549) cells
Presenter: Jose Kenneth Narag
Session: Cocktail & Poster Display session
Resources:
Abstract
21P - Hsa_circ_0009061 inhibits the progression of bladder cancer through the miR-889-3p/CPEB3 axis
Presenter: Minkang Wu
Session: Cocktail & Poster Display session
Resources:
Abstract
22P - Exploring exportin-1 as a therapeutic vulnerability in lung squamous cell carcinoma
Presenter: Vidushi Durani
Session: Cocktail & Poster Display session
Resources:
Abstract
23P - Identification of HPSE as potential novel therapeutic target for lung adenocarcinoma patients
Presenter: Samuel Doré
Session: Cocktail & Poster Display session
Resources:
Abstract
24P - High-throughput plasma proteomics profiling in early breast cancer
Presenter: Isabella Lombardo
Session: Cocktail & Poster Display session
Resources:
Abstract
25P - Immunohistochemical analysis of ROR1 and BMI-1 expression in luminal breast cancer
Presenter: Sergey Vtorushin
Session: Cocktail & Poster Display session
Resources:
Abstract
26P - Associations between cancer stem cells (CSC) markers and androgen (AR) and estrogen (ER) receptors expression in prostate cancer (PCa)
Presenter: Marina Puchinskaya
Session: Cocktail & Poster Display session
Resources:
Abstract
27P - Proteomic profiling reveals organ-specific differences in metastases and identifies potential biomarkers for recurrence risk in localized colon cancer
Presenter: Blanca García-Micó
Session: Cocktail & Poster Display session
Resources:
Abstract
28P - Collagen-activated signalling pathway is significantly hypermethylated in high-grade serous ovarian cancer (HGSOC) patients treated with platinum-containing neoadjuvant chemotherapy (NACT)
Presenter: Jose Alejandro Perez Fidalgo
Session: Cocktail & Poster Display session
Resources:
Abstract
29P - Quantitative tissue analysis reveal adenylate kinase 2 protein signatures: Therapeutic target for meningioma
Presenter: Rashmi Rana
Session: Cocktail & Poster Display session
Resources:
Abstract